Financials data is unavailable for this security.
View more
Year on year Agios Pharmaceuticals Inc had net income fall from a gain of 673.73m to a loss of 412.78m despite a 48.03% increase in revenues from 36.50m to 54.03m. An increase in the cost of goods sold as a percentage of sales from 11.41% to 11.74% was a component in the falling net income despite rising revenues.
| Gross margin | 88.26% |
|---|---|
| Net profit margin | -764.01% |
| Operating margin | -873.87% |
| Return on assets | -27.89% |
|---|---|
| Return on equity | -30.20% |
| Return on investment | -29.52% |
More ▼
Cash flow in USDView more
In 2025, Agios Pharmaceuticals Inc increased its cash reserves by 16.90%, or 12.88m. Cash Flow from Investing totalled 377.18m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 372.98m for operations while cash generated from financing totalled 8.68m.
| Cash flow per share | -7.03 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 20.41 |
|---|---|
| Tangible book value per share | 20.41 |
More ▼
Balance sheet in USDView more
| Current ratio | 11.46 |
|---|---|
| Quick ratio | 11.06 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
